
Shuttle Pharmaceuticals Holdings, Inc. announced the appointment of Christopher Cooper as interim Co-Chief Executive Officer focused on enhancing the Company’s capital markets and business capabilities. Dr. Anatoly Dritschilo, Chairman of the Company’s Board of Directors, will continue in his role as Co-CEO overseeing the Company’s scientific and clinical trial activities.
“I am excited to welcome Christopher Cooper as Co-CEO of Shuttle Pharma,” commented Dr. Anatoly Dritschilo, Chairman of the Board and CEO of Shuttle Pharma. “Christopher brings a wealth of business acumen which when balanced with the inherent scientific expertise of the entire Shuttle Pharma team should allow for a highly effective executive structure that should inspire confidence going forward. I believe this appointment will enhance decision-making, supports fundraising, and prepares us for the accelerated achievement of key milestones in the future.”
Christopher Cooper added, “I am enthusiastic to join the incredibly talented team at Shuttle Pharma as we aim to improve the lives of millions impacted by cancer and bring hope to patients and families around the world. The Co-CEO structure will allow for parallel execution of R&D, regulatory and general business operations. I look forward to leveraging my business experience to allow Dr. Dritschilo to focus more of his efforts going forward on the successful execution of the Company’s ongoing key Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma and continued advancement of the Diagnostics subsidiary.”
Mr. Cooper has more than 27 years of experience in management and finance, having worked in the oil and gas, telecommunications and technology industries. In addition to his appointment as Interim Co-CEO of the Shuttle Pharma, Mr. Cooper also serves as President, CEO and Founder of First Towers & Fiber Corp., a telecommunications infrastructure company with operations in Latin America, positions he has held since 2017. From 2010 until 2017, Mr. Cooper served as President and CEO of Aroway Energy, Inc., a Vancouver, British Columbia-based oil and gas company, where he was responsible for overseeing day to day operations, financial reporting, and oversaw acquisitions and debt and equity financing. From 1998 until 2010, Mr. Cooper served as a Corporate Consultant to various companies in the technology and resources sectors, oversaw restricting activities for several distressed public companies, and was responsible for raising more than $100 million in debt and equity for his clients. Mr. Cooper received his MBA from Dowling College in 1995 and his BBA in Business Administration from Hofstra University.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!